论文部分内容阅读
目的 研究普乐可复 (FK5 0 6 )对肾移植患者免疫抑制作用的疗效与安全性。方法 肾移植术后应用FK5 0 6免疫抑制治疗 82例 ,分为临床验证组 42例和切换治疗组 40例。结果 临床验证组有 40例 (95 .2 % )肾功能在 14d内恢复正常 ,1例 (2 .4% )发生急性排斥反应 ,经治疗逆转。切换治疗组有 2 4例肝功能逐渐恢复正常 ;3例移植肾发生急性肾小管坏死 (ATN)伴急性排斥反应 ,6例发生慢性排斥反应 ,4例发生难治性排斥反应 ,均经治疗后逆转 ;2例严重齿龈增生经治疗完全消退 ;1例腹痛消失。结论 FK5 0 6是一种安全高效的免疫抑制剂 ,排斥反应发生率低 ,毒副作用少 ,可与环孢素A(CsA)相媲美。对于难治性和慢性排斥反应、严重肝功能损害和牙龈增生等患者切换FK5 0 6治疗 ,是一种较好的方法。
Objective To study the efficacy and safety of Prograf (FK506) on immunosuppression in renal transplant recipients. Methods 82 cases of FK506 immunosuppressive therapy after renal transplantation were divided into clinical validation group (n = 42) and switch treatment group (n = 40). Results In the clinical validation group, 40 cases (95.2%) of renal function returned to normal within 14 days and 1 case (2.4%) had acute rejection reaction, which was reversed after treatment. In the switching treatment group, 24 cases of liver function returned to normal gradually; 3 cases of acute renal tubular necrosis (ATN) with acute rejection, 6 cases of chronic rejection, 4 cases of refractory rejection, all after treatment Reversed; 2 cases of severe gingival hyperplasia completely disappeared after treatment; 1 case of abdominal pain disappeared. Conclusion FK506 is a safe and effective immunosuppressive agent with low incidence of rejection and few side effects. It can be compared with CsA. For refractory and chronic rejection, severe liver damage and gingival hyperplasia and other patients switch FK506 treatment is a better method.